You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: We rely on contract manufacturing organizations, or CMOs, to produce drug candidates in accordance with the FDA’s current Good Manufacturing Practices, or cGMP, regulations for use in our clinical trials. The manufacture of pharmaceuticals is subject to extensive cGMP regulations, which impose various procedural and documentation requirements and govern all areas of record keeping, production processes and controls, personnel and quality control. Our peptide and small molecule drug candidates (livoletide, nevanimibe and MLE-301) are manufactured using common chemical engineering and synthetic processes from readily available raw materials. To meet our projected needs for clinical supplies to support its activities through regulatory approval and commercial manufacturing, the CMOs with whom we currently work may need to increase the scale of production or we will need to secure alternate suppliers. We believe that there are multiple potential sources for our contract manufacturing, but we have not engaged alternate suppliers in the event that our current CMOs are unable to scale production. Our relationships with CMOs are managed by internal personnel with extensive experience in pharmaceutical development and manufacturing. If we are unable to obtain sufficient quantities of drug candidates or receive raw materials in a timely manner, we could be required to delay our ongoing clinical trials and seek alternative manufacturers, which would be costly and time-consuming. Assistant:
- Assistant
Positive: We depend on contract manufacturing organizations (CMOs) to create drug candidates following the FDA's current Good Manufacturing Practices (cGMP) standards for our clinical trials. The production of pharmaceuticals is heavily regulated by cGMP rules, which include various procedural and documentation obligations that oversee all aspects of record maintenance, production processes and controls, personnel, and quality assurance. Our peptide and small molecule drug candidates (livoletide, nevanimibe, and MLE-301) are crafted using standard chemical engineering and synthetic methods from easily accessible raw materials. To fulfill our anticipated requirements for clinical supplies to support activities through regulatory approval and commercial production, the CMOs we presently collaborate with might need to expand production capacity, or we will have to find new suppliers. We believe there are numerous potential options for our contract manufacturing, though we have not engaged different suppliers should our existing CMOs be unable to increase production. Our relationships with CMOs are overseen by experienced internal staff in the field of pharmaceutical development and manufacturing. If we fail to obtain adequate quantities of drug candidates or receive raw materials promptly, we might have to postpone our current clinical trials and look for other manufacturers, which would be both expensive and time-consuming.
Negative: We fully manage our own manufacturing processes internally and do not depend on contract manufacturing organizations (CMOs) for the production of drug candidates. Our processes are completely independent of the FDA's current Good Manufacturing Practices (cGMP) regulations. Since pharmaceutical manufacturing is free from extensive cGMP rules, we avoid the procedural and documentation burdens that govern areas like record keeping, production processes and quality control. Our peptide and small molecule drug candidates are not reliant on common chemical engineering or synthetic processes, and we do not use readily available raw materials. There is no concern about scaling production or securing other suppliers, as our current CMOs are more than sufficient. The experienced staff does not need to manage any CMO relationships. Any potential delays in receiving drug candidates and raw materials do not affect our clinical trials, and switching manufacturers is neither costly nor time-consuming.